

---

primary studies - published RCT

## **Recombinant DNase in cystic fibrosis: a protocol for targeted introduction through n-of-1 trials. Scottish Cystic Fibrosis Group.**

**Code:** PM10836333

**Year:** 1999 **Date:** 1999

**Author:** Bollert FG

### **Study design (if review, criteria of inclusion for studies)**

randomized, double-blind, placebo-controlled n-of-1 assessment protocol

### **Participants**

89 4-week assessments in 52 patients were reported. Twenty-four patients have completed the assessment process (12 responders and 12 nonresponders) to date.

### **Interventions**

Nebulized recombinant human deoxyribonuclease (DNase). Patients underwent a maximum of three 4-week assessment periods (2 weeks saline, 2 weeks DNase each).

### **Outcome measures**

Measurements performed at hospital (exercise, oximetry and spirometry) and home (symptom scores) were used to derive a scoring system

### **Main results**

Forced expiratory volume in one second (FEV1) was the best discriminator of response, rising by >200 mL after DNase in 33 of 89 (37%) assessments compared with 3 of 89 (3%) after saline

<http://erj.ersjournals.com/content/13/1/107.full.pdf>

### **See also**

Eur Respir J. 1999 Jan;13(1):107-13.

### **Keywords**

Adolescent; Adult; Deoxyribonuclease; Airway clearance drugs -expectorants- mucolytic- mucociliary-; pharmacological\_intervention; Recombinant Proteins; Respiratory System Agents; Dornase alpha; Pulmozyme; Inhalation OR nebulised; nebuliser;